LLY241213P745000
- 0.59
- +0.14+31.11%
Eli Lilly and Co Newsroom
Trump rings the opening bell for the NYSE: The stock market is everything, and significant actions will be taken regarding Cryptos.
On Thursday, Donald Trump rang the opening bell at the NYSE. He emphasized the importance of the stock market, stating that the stock market is everything, and plans to take significant actions regarding Cryptos, lower the corporate tax rate to 15%, and increase Petroleum Extraction to alleviate the current inflationary pressures.
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
"Person of the Year" Trump rings the opening bell at the NYSE, emphasizing that "the stock market is everything."
On December 12, the elected President Trump was named Time Magazine's Person of the Year for 2024, ringing the opening bell at the NYSE that day; Trump rang the bell with the CEO of ICE and the CEO of Time Magazine, along with the president of the NYSE, while the CEOs of companies such as Goldman Sachs and Citigroup were present; Trump promised an "unprecedented economy," planned to increase oil drilling to reduce inflation, and committed to lowering the corporate tax rate to 15%.
Top 20 by transaction volume | Performance guidance fell short of expectations, Adobe dropped nearly 14%; MicroStrategy fell over 4%.
On Thursday, the top stock by trading volume in the U.S. market was Tesla, which closed down 1.57% with a trading volume of 36.778 billion USD; the second was NVIDIA, which closed down 1.41% with a trading volume of 21.623 billion USD; the eleventh was UnitedHealth Group, which closed down 3.33% with a trading volume of 4.899 billion USD.
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Has Eli Lilly and Co's tirzepatide "defeated" Novo-Nordisk A/S's semaglutide? The competition for weight loss drugs is moving towards "precision breakthroughs."
Industry experts point out that the competition for weight loss drugs is no longer just about rapid weight loss, but requires a "targeted breakthrough" in safety and sustainability aspects, such as reducing weight regain, minimizing muscle loss, increasing medication convenience, and reducing side effects.
Why Eli Lilly and Company (LLY) Is the Best Safe Stock to Buy According to Analysts?
3 Stocks to Keep an Eye on After Dividend Hike Announcement
Xi'an Global Printing (002799.SZ): Has maintained a good cooperative relationship with Eli Lilly and Co and Novo-Nordisk A/S.
Gelonghui reported on December 12 that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that the company has maintained a good cooperative relationship with Eli Lilly and Co, Novo-Nordisk A/S, and other enterprises. In the future, the company will continue to strengthen market development efforts and expand its customer base.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900
Swiss Market Index Recovers Ahead of Interest Rate Decision
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Eli Lilly Ties Up With Ro to Improve Availability of Weight-Loss Drug Zepbound in Vials
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997